STOCK TITAN

Aimei Health flagged for Nasdaq market value shortfall

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Aimei Health Technology Co., Ltd. (AFJK) reports that Nasdaq has notified it that its Market Value of Listed Securities (MVLS) has been below $50,000,000 and its Market Value of Publicly Held Shares (MVPHS) has been below $15,000,000 for the last 30 consecutive business days, violating Nasdaq Global Market continued listing standards.

The company has two separate 180-day compliance periods, through February 17, 2027, to have MVLS at or above $50,000,000 and MVPHS at or above $15,000,000 for at least 10 consecutive business days. AFJK’s shares continue to trade on the Nasdaq Global Market, but failure to regain compliance could lead to delisting or a transfer to the Nasdaq Capital Market.

Positive

  • None.

Negative

  • AFJK has fallen below Nasdaq Global Market thresholds of $50,000,000 MVLS and $15,000,000 MVPHS for 30 consecutive business days, creating a risk of potential delisting if compliance is not regained.
  • AFJK faces a deadline of February 17, 2027 to restore both MVLS and MVPHS to required levels for at least 10 consecutive business days, increasing listing-risk uncertainty.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
MVLS minimum requirement $50,000,000 Minimum Market Value of Listed Securities required under Nasdaq Listing Rule 5450(b)(2)(A)
MVPHS minimum requirement $15,000,000 Minimum Market Value of Publicly Held Shares required under Nasdaq Listing Rule 5450(b)(2)(C)
Business days below thresholds 30 business days Period during which MVLS and MVPHS were below Nasdaq minimums
Compliance period length 180 calendar days Time allowed to regain compliance for both MVLS and MVPHS
Compliance deadline February 17, 2027 End of 180-day compliance periods for MVLS and MVPHS
Required compliant trading span 10 consecutive business days Duration MVLS or MVPHS must meet or exceed thresholds to regain compliance
Market Value of Listed Securities financial
"the Company’s Market Value of Listed Securities (“MVLS”) was below $50,000,000"
Market value of listed securities is the market value of the shares a company has listed on an exchange, calculated as the closing bid price multiplied by the number of listed shares. Exchanges use it as a continued-listing standard, so a company that stays under the required minimum receives a deficiency notice and is given a set period to recover before facing delisting.
Market Value of Publicly Held Shares financial
"the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below $15,000,000"
The market value of publicly held shares is the total dollar worth of a company’s shares that are available to outside investors, calculated by multiplying the current market price by the number of shares held by the public (the “float”). It matters because it tells investors how much of the company is actually tradable and how the market is pricing that tradable portion—like a price tag on the items on a store shelf, it affects liquidity, volatility and how easy it is to buy or sell a meaningful stake.
Nasdaq Global Market market
"minimum MVLS required for continued listing on The Nasdaq Global Market"
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
Nasdaq Capital Market market
"applying to transfer its securities to The Nasdaq Capital Market"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

FAQ

What Nasdaq deficiency notices did AFJK receive?

AFJK received two Nasdaq notices stating that, for 30 consecutive business days, its Market Value of Listed Securities was below $50,000,000 and its Market Value of Publicly Held Shares was below $15,000,000, both below Nasdaq Global Market continued listing standards.

Does AFJK face delisting from Nasdaq Global Market?

AFJK faces a potential delisting risk. If it does not regain compliance with MVLS and MVPHS requirements by February 17, 2027, Nasdaq may notify the company that its securities are subject to delisting, though a transfer to the Nasdaq Capital Market could be considered.

How long does AFJK have to regain MVLS compliance?

AFJK has 180 calendar days from the MVLS notice, until February 17, 2027, to regain compliance by having its MVLS close at $50,000,000 or more for at least 10 consecutive business days.

What is required for AFJK to regain MVPHS compliance?

To regain MVPHS compliance, AFJK must achieve a Market Value of Publicly Held Shares of at least $15,000,000 for a minimum of 10 consecutive business days within the 180-day compliance period ending February 17, 2027.

Is AFJK still trading on Nasdaq and under what symbol?

Yes. AFJK’s ordinary shares continue to trade on the Nasdaq Global Market under the symbol “AFJK”, while it works to address the MVLS and MVPHS deficiencies and comply with other Nasdaq listing requirements.

What alternatives does AFJK have if it cannot meet Nasdaq Global Market standards?

If AFJK cannot regain compliance with Nasdaq Global Market standards, it may apply to transfer its securities to the Nasdaq Capital Market, provided it satisfies that market’s continued listing requirements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
false 0001979005 0001979005 2026-08-21 2026-08-21 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2026-08-21 2026-08-21 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2026-08-21 2026-08-21 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2026-08-21 2026-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

August 21, 2026

Date of Report (Date of earliest event reported)

 

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-41880   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

10 East 53rd Street, Suite 3001

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

86-13758131392

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share   AFJK   The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share   AFJKR   The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right   AFJKU   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On August 21, 2026, Aimei Health Technology Co., Ltd (the “Company”) received a letter (the “MVLS Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, for the last 30 consecutive business days, the Company’s Market Value of Listed Securities (“MVLS”) was below $50,000,000, which is the minimum MVLS required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(A). On the same date, the Company received a separate letter (the “MVPHS Notice” and, together with the MVLS Notice, the “Notices”) from the Nasdaq Listing Qualifications Department, notifying the Company that, for the last 30 consecutive business days, the Company’s Market Value of Publicly Held Shares (“MVPHS”) was below $15,000,000, which is the minimum MVPHS required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(b)(2)(C). The Notices have no immediate effect on the listing of the Company’s ordinary shares, which will continue to be traded on The Nasdaq Global Market under the symbol “AFJK,” subject to the Company’s compliance with the other Nasdaq listing requirements.

 

In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company is provided a compliance period of 180 calendar days from the date of the MVLS Notice, or until February 17, 2027, to regain compliance with the minimum MVLS requirement. If, at any time during this compliance period, the Company’s MVLS closes at $50,000,000 or more for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed. In accordance with Nasdaq Listing Rule 5810(c)(3)(D), the Company has a compliance period of 180 calendar days from the date of the MVPHS Notice, or until February 17, 2027, to regain compliance with the minimum MVPHS requirement. If, at any time during this compliance period, the Company’s MVPHS closes at $15,000,000 or more for a minimum of 10 consecutive business days, Nasdaq will provide the Company written confirmation of compliance and this matter will be closed.

 

If the Company does not regain compliance with the minimum MVLS or MVPHS requirements before the expiration of the applicable compliance period, the Company will receive written notification that its securities are subject to delisting. Alternatively, the Company may consider applying to transfer its securities to The Nasdaq Capital Market, provided that it satisfies the applicable continued listing requirements of The Nasdaq Capital Market. The Company intends to monitor its MVLS and MVPHS and may consider available options to regain compliance with the applicable Nasdaq Listing Rules. There can be no assurance that the Company will successfully maintain the listing of its ordinary shares on The Nasdaq Global Market or, if transferred, on The Nasdaq Capital Market.

 

Item 9.01. Exhibits.

 

Exhibit No.   Description
     
104   Cover Page Interactive Data File (formatted in Inline XBRL).

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: August 25, 2026

 

  Aimei Health Technology Co., Ltd
     
  By: /s/ Junheng Xie
  Name: Junheng Xie
  Title: Chief Executive Officer and Director
    (Principal Executive Officer)

 

3

 

Filing Exhibits & Attachments

4 documents